Bayer secures FDA approval for hemophilia A treatment drug Jivi

In a major advancement for hemophilia A therapy, Bayer's recombinant factor VIII (rFVIII) replacement therapy, Jivi (BAY94-9027), has received approval from the U.S. Food and ... Read More